Two terms appear side by side in pharmaceutical sourcing enquiries almost every week: comparator drug and reference listed drug (RLD). They are frequently used as though they mean the same thing. They do not. One belongs to clinical trial law, the other to United States generic drug approval, and each carries a different set of sourcing, documentation, and market-of-origin requirements.

A purchase specification that names the wrong term will usually still produce a delivery. The problem tends to surface months later, when a regulator asks a question about origin, strength, or provenance that the material on hand cannot answer. This article separates the two terms, adds the two related concepts that account for most of the remaining confusion, and sets out which one you actually need in each situation.

What Is a Comparator Drug?

A comparator drug is the medicine used as the reference arm of a clinical trial, against which the investigational product is measured. It may be an active licensed medicine representing the current standard of care, or it may be a placebo.

Article 2(5) of Regulation (EU) No 536/2014 defines an investigational medicinal product (IMP) as a medicinal product being tested or used as a reference, including as a placebo, in a clinical trial. The European Commission's questions and answers on the Regulation confirm directly that an authorised medicinal product used as a comparator in a trial is considered an IMP.

ICH E6(R3), the current Good Clinical Practice guideline, takes the same position. It defines an investigational product as a pharmaceutical form of an active ingredient or placebo being tested or used as a reference in a clinical trial, and explicitly includes an authorised product when used or assembled differently from the approved form, used for an unapproved indication, or used to gain further information about an approved use. E6(R3) was adopted on 6 January 2025 and came into force in the European Union on 23 July 2025.

The operative word is reference, meaning the reference arm of a study. A comparator exists because a protocol needs something to compare against. Its defining context is a trial with participants, endpoints, and ethics approval, and the practical consequence is that a box of a well known branded medicine bought for a trial is not ordinary stock. It is regulated material.

What Is a Reference Listed Drug (RLD)?

Federal regulations at 21 CFR 314.3 define the RLD as the listed drug identified by the FDA as the drug product upon which an applicant relies in seeking approval of its ANDA. The generic applicant must demonstrate that its proposed product is the same as the RLD in active ingredient, dosage form, route of administration, strength, labelling, and conditions of use.

The RLD is a creature of United States generic drug law, originating in the Hatch-Waxman framework. Its purpose is not to run a study but to establish a legal basis for approval. The applicant relies on the FDA's earlier finding that the RLD is safe and effective rather than repeating the full development programme.

RLDs are identified in the publication formally titled Approved Drug Products with Therapeutic Equivalence Evaluations, universally known as the Orange Book. Listed drugs identified as RLDs represent products upon which an applicant can rely in seeking ANDA approval. A product can remain an RLD after it stops being marketed, provided the withdrawal was not for reasons of safety or effectiveness, in which case it appears in the Orange Book's Discontinued Drug Product List.

RLD vs Reference Standard: The Distinction That Causes Most Sourcing Errors

This is the point most published guidance on the topic gets wrong, and it is worth understanding precisely.

The RLD is the product a proposed generic must match on active ingredient, dosage form, route, strength, labelling, and conditions of use. The reference standard is the specific drug product the FDA selects that an ANDA applicant must physically use when conducting an in vivo bioequivalence study required for approval.

The FDA generally selects a single reference standard, and ordinarily it selects the RLD. However, the two can diverge. Where an RLD has been withdrawn from sale and the FDA has determined the withdrawal was not for reasons of safety or effectiveness, the agency may select an approved generic as the reference standard instead. In that situation the applicant compares labelling and formulation to the RLD but runs its bioequivalence study against a different product entirely.

Where multiple strengths of a dosage form exist, the FDA usually designates the highest strength as the reference standard. A team that orders a mid-range strength because it matches the intended generic has sourced the wrong material for the study.

Do the EU and Biologics Use the Same Terms?

No, and applying United States terminology to an EU submission is a common cause of confusion in multinational programmes.

European Union: Reference Medicinal Product

The EU has no RLD. A generic application under Article 10(1) of Directive 2001/83/EC relies instead on a reference medicinal product: a product granted a marketing authorisation on the basis of a complete dossier, authorised in the EEA, and to which the generic application refers by demonstrating bioequivalence through appropriate bioavailability studies.

EMA guidance requires that the product used in the bioequivalence study forms part of the global marketing authorisation of the reference medicinal product, and that the applicant's choice of reference product is justified within the dossier.

Biologics: Reference Product

For biological products, neither term applies. A biosimilar developed under the United States 351(k) pathway references a reference product, a biological product licensed under section 351(a) of the Public Health Service Act. These are listed in the Purple Book, formally the Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. Reference products carry twelve years of exclusivity from first licensure, against five years of data exclusivity for a new chemical entity.

Comparator vs RLD: Side by Side

When Do You Need a Comparator, and When Do You Need an RLD?

Ask what the material is actually for. If it will be administered to trial participants as the control arm of a study, you need a comparator. If it will be used to demonstrate sameness or bioequivalence for a generic filing, you need an RLD, and you should confirm the reference standard separately. Laboratory and formulation work sits in the second group even though no participants are involved.

Why the Distinction Changes How You Source

Three differences matter most in practice.

• Origin tolerance. A protocol may permit a comparator from any of several markets where the same formulation is authorised. An RLD supporting a United States filing generally will not: the FDA expects US-market product, and EU generic applications expect an EEA-authorised reference medicinal product. Origin evidence is therefore the single most important document in an RLD purchase.
• Volume and time profile. Comparator supply runs for the life of the trial and almost always requires resupply, which means planning for batch changes and shelf life across a multi-year window. RLD supply is typically a defined campaign, but often needed quickly and at a specific strength that may be constrained.
• Release and labelling. Comparators used in EU trials require certification by a Qualified Person before release, together with trial specific labelling under Annex 13 of the EU GMP Guide. RLD material used for laboratory or bioequivalence work does not go through QP release, but the batch documentation still has to survive inspection years later.

What Mistakes Cause the Most Delay?

• Using the terms interchangeably in a specification. Writing "RLD required" for a trial control arm, or "comparator" for an ANDA programme, leaves the supplier to guess at origin, quantity, and documentation.
• Assuming the RLD and reference standard are the same. They usually are, but when they are not, the bioequivalence study is run against the wrong product.
• Ordering the wrong strength. The FDA typically designates the highest strength as the reference standard, which may not be the strength the generic targets.
• Sourcing from the wrong market. An EU-market pack of the same brand will not support a US ANDA, however identical it looks.
• Looking for a biologic in the Orange Book. Biological reference products are listed in the Purple Book, under a different statute.
• Leaving documentation until after delivery. Certificate of Analysis, Certificate of Origin, and provenance evidence belong in the purchase agreement, not in a follow-up email.

How Should You Brief a Supplier?

Whichever material you need, a good specification answers six questions before a supplier has to ask: the molecule and brand, the marketing authorisation holder, the strength and dosage form, the required country of origin, the intended use (trial control arm, bioequivalence study, laboratory comparison, or dossier work), and the documentation pack required. Add the quantity and the date it is needed on site.

Suppliers who work regularly with regulated programmes will respond with availability, origin options, lead time, and a documentation list. If a supplier quotes without asking about intended use or market of origin, that is a useful signal in itself.

For a fuller walkthrough of the trial side of this process, see our companion guide on how to source comparator drugs for clinical trials.

References

• European Commission. Clinical Trials Regulation (EU) No 536/2014, Questions and Answers, Article 2(2)(5) and section 1.15. The rules governing medicinal products in the European Union, Volume 10.
• International Council for Harmonisation. ICH E6(R3) Guideline for Good Clinical Practice. Adopted 6 January 2025; applicable in the European Union from 23 July 2025. European Medicines Agency and US Food and Drug Administration.
• Electronic Code of Federal Regulations. 21 CFR 314.3 – Definitions. ecfr.gov
• US Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book), Preface and Discontinued Drug Product List.
• US Food and Drug Administration. Guidance for Industry: Referencing Approved Drug Products in ANDA Submissions. Office of Generic Drugs, CDER.
• Directive 2001/83/EC of the European Parliament and of the Council, Article 10(1) and 10(2)(b), on the Community code relating to medicinal products for human use.
• European Medicines Agency. Generic and Hybrid Applications, pre-authorisation guidance. ema.europa.eu
• US Food and Drug Administration. Purple Book: Lists of Licensed Biological Products with Reference Product Exclusivity and Biosimilarity or Interchangeability Evaluations. fda.gov
• Electronic Code of Federal Regulations. 21 CFR 314.161 – Determination of reasons for voluntary withdrawal of a listed drug. ecfr.gov
• US Food and Drug Administration. Approved Drug Products with Therapeutic Equivalence Evaluations, 46th Edition, reference standard selection guidance.
• European Medicines Agency. Guideline on the Investigation of Bioequivalence (Rev. 1). ema.europa.eu
• Biologics Price Competition and Innovation Act of 2009 (BPCIA), Public Law 111-148, section 7002; Public Health Service Act sections 351(a) and 351(k).
• European Commission. EudraLex Volume 4, EU Guidelines for Good Manufacturing Practice, Annex 13: Investigational Medicinal Products.

Compiled from primary regulatory sources (US Code of Federal Regulations, FDA guidance and product listings, EU Directives and Regulations, EMA scientific guidelines, and ICH guidelines) available as of July 2026. Regulatory designations including reference listed drug and reference standard status are determined by the relevant competent authority and are subject to change; applicants should verify current listings directly.